| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
David J. Moss
Also a director
President, CEO, Secretary, Treasurer and Director
|
56 | Not stated | 2015 | $1,845,179 | |
|
Cory Ellspermann
Chief Financial Officer
|
53 |
Since 2025
1 year
|
Not stated | $619,227 | |
|
Mark Lowdell
Chief Scientific Officer
|
64 |
Since 2015
11 years
|
Not stated | $1,452,236 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Payments to UCL for medical research performed on behalf of the Company.
Medical research performed for the Company by AmplifyBio; the Company recorded a payable of $26,000 at December 31, 2025 and paid AmplifyBio $41,000 during 2025.
Loading...
